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The human body’s general inflammatory response, orchestrated by molecular signals, functions 
in both adaptive and innate immunity, allowing the body to isolate injurious agents. Unchecked, 
it can evolve into storms where the signals for adaptive and innate immunity are produced in 
excessive amounts, resulting in a severe inflammatory response. It is critical to understand how 
these signals are induced and ultimately stopped, since too little or too much of an inflammatory 
response can lead to diseased states. In light of recent events, it is imperative to understand the 
key inflammatory response elements that appear to be the source of more severe ailments 
resulting from a SARS-CoV-2 viral infection, known as Covid-19, to mitigate the effects of the 
pandemic. The more severe cases of Covid-19 are characterized by a severe inflammatory 
response resulting in tissue damage. Two possible culprits are a bradykinin storm or an 
interleukin-6 (IL-6)-mediated cytokine storm, where in both systems, the release of certain 
signals subsequently signal the production of even more of the same signal, resulting in a vicious 
positive feedback loop (2, 10, 21). Recent evidence points towards bradykinin, a substrate of the 
angiotensin-converting enzyme (ACE), as being responsible for the severe Covid-19 
inflammatory response (1-4). This is because the SARS-CoV-2 virus targets ACE, a cell surface 
protein directly involved in bradykinin metabolism and the renin-angiotensin system (10). 
Bradykinin storm symptoms align similarly with what is seen in Covid-19 infection (3). I 
hypothesize based on SARS-CoV-2’s direct interference with the renin-angiotensin 
pathway, that it is the bradykinin storm responsible for the more severe complications of 
Covid-19, as opposed to a cytokine storm. However, isolating one storm over the other has 
yet to be tested. I aim to determine which storm induces the severe responses of Covid-19, 
such as tissue damage, hypoxemia, and fluid buildup. To determine the nature of the storm 
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that induces the severe responses of Covid-19, I will test how Actemra, a cytokine IL-6 inhibitor, 
and icatibant, a bradykinin inhibitor, prevent such responses in a Covid-19 mouse model. The 
possibility exists that the systems work together, where one system induces the other or they act 
in parallel.  
 
Specific Aim 1: Is the bradykinin storm solely responsible for the severe symptoms 
resulting from the overactive inflammatory responses in Covid-19 patients? 
 I will have four groups of humanized transgenic mouse K18-hACE2, which expresses the 
same human ACE receptor previously used when studying the first SARS outbreak in 2003 (5). I 
will infect the transgenic mouse with SARS-CoV-2, which will allow us to observe the 
symptoms found in patients with chronic infections, without using human patients. Previous 
studies have indicated that this mutated mice exhibits similar symptoms as humans upon 
infection (5). I will study four groups of these mice: group 1 treated with the bradykinin 
inhibitor; group 2 treated with the IL-6 inhibitor; group 3 given both inhibitors to test whether 
both pathways play a role; and group 4 is the control. I will be testing which drug will be more 
effective in treating the symptoms observed in the groups. 
Specific Aim 2: Does a bradykinin storm lead to a cytokine storm, or the opposite, if both 
systems play a role? 
 If group 3 of the K18-hACE2 mice from Aim 1 have alleviated symptoms due to the 
presence of both inhibitors, then bradykinin and cytokines may induce the other or work in 
parallel. To test this, I will create a loss-of-function mutation and a gain-of-function mutation in 
K18-hACE2 mice. Based on bradykinin’s direct interaction with the ACE protein, I expect that a 
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bradykinin storm will be responsible for triggering a cytokine storm, if what is observed in the 
third group of mice holds to be true. 
 
BACKGROUND AND SIGNIFICANCE 
Bradykinin and Renin-Angiotensin System 
 Bradykinin (BK) is a nonapeptide produced from a decapeptide and is normally found in 
the blood in its inactive form (6). BK is an extremely potent vasodilator and is a physiological 
mediator of anaphylaxis, which is caused by mast cell activation and release, following the 
binding of specific antigens to IgE antibodies on mast cell membranes (6). BK acts with the 
renin-angiotensin system to regulate blood flow (34).  
The renin-angiotensin system functions in clearing renal waste and maintaining blood 
flow. A reduction in blood flow will release renin, which converts the hormone angiotensinogen 
into angiotensin 1, which in turn will be converted into the active angiotensin 2 (Fig 1; ref. 35). 
Angiotensin 2 acts on the peripheral arteries of the body to increase blood pressure via 
vasoconstriction and signals the adrenal glands to produce aldosterone and promote reabsorption 
of salts and water by the kidneys (Fig 1; ref. 35).  
The counter to this system involves the membrane protein ACE2. ACE2 is a functional 
receptor expressed in the lungs, kidney, heart, and intestines (12). It consists of an extracellular 
N-terminal peptidase domain and a C-terminal transmembrane anchor (12). The active form of 
ACE2 is induced by the enzyme sheddase, which cleaves the external domain of the ACE2 
protein (Fig 2). This cleaved ACE2 is released into the bloodstream, where it interacts with 
angiotensin 2, a vasoconstrictor (Fig 2; ref. 35). The conversion of angiotensin 2 to angiotensin 
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1-7, a powerful vasodilator and antioxidant, by ACE2 effectively inactivates angiotensin 2 and 









 The bradykinin storm occurs when ACE2 is depleted, since this leads to increased levels 
of DABK, a bioactive metabolite of BK, which is associated with lung injury and inflammation 
(10). Depletion of ACE2 causes constant vasoconstriction that is induced by the renin-
angiotensin system, which can lead to tissue damage (9, 10). High levels of DABK trigger 
endoplasmic reticulum stress, mitochondrial death signaling, ACE2 downregulation, 
Fig 2. The activity of sheddase counters the activity of the renin-angiotensin system. 
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upregulation of proinflammatory genes, all of which guide the cell into apoptosis (10).  Cell 
injury further increases the severity of the response, as it upregulates the BK B1 receptor, 
amplifying the DABK-mediated inflammation and damage (10, 18). This results in a positive 
feedback loop of inflammation and injury.  
 
Cytokine Storm 
Cytokines are a variety of proteins that are secreted by cells as signals that act on many 
systems of the body (17). They have autocrine, paracrine, and endocrine activities and induce a 
variety of responses (17). There are five major types of cytokines: interferons, which regulate 
innate immunity and activate antiviral properties; interleukins, which affect the growth and 
differentiation of leukocytes and can be proinflammatory; chemokines that control chemotaxis 
and leukocyte recruitment; colony-stimulating factors, which stimulate hematopoietic progenitor 
cell proliferation and differentiation; and lastly, tumor necrosis factors, which activate cytotoxic 
T lymphocytes (17). Cytokines alone are rather potent: when the signaling system produces too 
many, it can result in a positive feedback loop and a severe inflammatory response. This process 
is referred to as a cytokine storm (17). Inflammation begins at a local site and spreads throughout 
the body through the circulatory system. When localized within a tissue, vascular leukocytes and 
plasma proteins reach the extra-vascular site of injury and generate pain (17). Severe 
inflammation damages tissue structures and the scar tissues that form can result in organ 
dysfunction and long-term damage (17). In humans, a cytokine storm can result in collagen 
deposition in the lungs, which damage the lungs and lead to co-morbidities such as opportunistic 
bacterial, fungal, or viral infections and sepsis (17). Interleukin-1β (IL-1β) and interleukin-8 (IL-
8) initiate the storm, appearing within the first few hours of a response and are followed by a 
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sustained increase in interleukin-6 (IL-6) (17). Sustained levels of IL-6 increase the severity of 
the storm (17). 
 
The SARS-CoV-2 Viral infection and Covid-19 
 SARS-CoV-2 is a newly emerged pathogen first identified in Wuhan, Hubei Province, 
China, in December 2019, which causes the disease Covid-19. Initially diagnosed as a viral-
induced pneumonia by clinicians, SARS-CoV-2 was eventually isolated in bronchoalveolar 
lavage fluid from Covid patients (2, 4, 12). Coronaviruses are serologically divided into four 
subfamilies: α, β, γ, and δ-coronaviruses, where the first two groups infect humans. Covid-19 
was identified to be from the β coronavirus family (11). SARS-CoV-2 is a positive-sense, single-
stranded RNA with a genome size of 29.9 kb and a nucleocapsid that is composed of genomic 
RNA and phosphorylated nucleocapsid proteins (12, 13). The genome is encapsulated by a 
phospholipid bilayer with two different spike proteins protruding from the membrane: a spike 
glycoprotein trimer common to all coronaviruses, and the hemagglutinin-esterase. SARS-CoV-2 
targets the human ACE2, the functional receptor in the renin-angiotensin system. The spike 
proteins of SARS-CoV-2 bind to ACE2, which results in the shedding of the S1 subunit of the 
spike protein and a conformational change in the S2 subunit (12). This allows membrane fusion 
with the host cell (12). SARS-CoV-2 causes the disease Covid-19, which results in a respiratory 
illness characterized by fever, cough, myalgia, sputum production, heloptysis, diarrhea and 
dyspnea (14). Severe cases of Covid-19 can result in comorbidities like sepsis, hypoxemia, 
pneumonia, fluid in the lungs, and tissue damage (7, 15, 16). 
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 The reason behind the severe symptoms of Covid-19 is hypothesized to be the direct 
result of a cytokine storm (2, 19, 24). The exact mechanisms of how a cytokine storm results in 
acute lung injury and acute respiratory distress syndrome in Covid-19 patients are unknown (25). 
In an analysis of 82 cases, 68 of which resulted in death, significantly higher levels of IL-6 were 
detected in more severe cases than in mild cases (26). Considering that sustained levels of IL-6 
are associated with increasing severity of cytokine storms, this lends to the possibility that a 
cytokine storm is responsible for the severe cases of Covid-19.  
 Very recently, however, bradykinin storms are gaining attention and are also considered a 
possibility, since SARS-CoV-2 targets the ACE2 protein and depletes it (10). Binding of Covid-
19 to the ACE2 protein prevents sheddase from binding and directly interferes with the renin-
angiotensin system (10). This interference triggers increased levels of DABK, which leads to a 
bradykinin storm (10). The bradykinin storm is also more associated with fluid in the lungs than 
is the case for a cytokine storm (10). This direct interference is what has led many, including 
myself, to believe that a bradykinin storm is responsible for the severity of chronic SARS-CoV-2 
infections (10).  
 It is imperative that we understand how SARS-CoV-2 interacts with the body and the 
mechanism by which it causes such severe damage and respiratory distress as we are still 
suffering through the Covid-19 pandemic. Understanding the mechanisms by which the two 
storms, bradykinin and cytokine, affect the body, separate or together, is crucial to mitigating the 
pandemic’s effect, saving lives, and producing effective treatments that we presently lack. 
Despite this being the first coronavirus pandemic, severe epidemics of the same family have 
existed before and will likely exist again, especially with the emergence of new and infectious 
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variants of SARS-CoV-2 (27). By understanding the mechanisms through which the virus acts 
on our physiology, we may be able to reduce the severity of future outbreaks and save lives.   
 
APPROACH 
Specific Aim 1: Is the bradykinin storm solely responsible for the severe symptoms resulting 
from the overactive inflammatory responses in Covid-19 patients? 
A. Rationale 
SARS-CoV-2 targets the cell surface protein ACE2, inhibiting the action of the enzyme 
sheddase and leading to increased DABK levels (10). An increase in DABK can lead to a 
bradykinin storm, thus the severe inflammatory responses in Covid-19 patients (10). However, 
the possibility exists that a cytokine storm is the cause for the severity of Covid-19. Inhibitors of 
IL-6, such as Actemra, have already been approved for distribution to patients with Covid-19 (8). 
 
B. Research Design: Viral Infection and Mice 
To test the cause behind the severe Covid-19 response, I plan to use the K18-hACE2 
transgenic mouse, which expresses the human ACE2 receptor, as well as the hallmark features of 
the human disease (28, 29). The mice are highly susceptible to SARS-CoV-1 infection and 
display symptoms characteristic of Covid-19 (28). Infection of SARS-CoV-1 in K18-hACE2 
leads to a 14-day infection period, where the infection is almost exclusively localized to the 
lungs (28). I chose this model due to these similarities between SARS-CoV-1, for which the 
model was initially created, and SARS-CoV-2, in addition to its expression of ACE2. Previous 
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studies on this mouse model showed that a cytokine storm induced the inflammatory response 
observed in the lungs and the spleen of the mice infected with SARS-CoV-2 (29). 
I will have four groups of specific-pathogen free, 4-to-5-week-old K18-hACE2 mice, 
where each group will have 20 mice—ten male and ten females. Three of the four groups will be 
infected with SARS-CoV-2 intranasally with 105 PFU (plaque forming units) of SARS-CoV-2 in 
a final volume of 50 µl following sedation. The final group, the control, will be mock-infected to 
ensure equal handling. I chose this concentration based on a previous study that observed an 
inflammatory response at this concentration (29). To prevent cross-group coprophagy and cross-
infection, the groups will not interact with one another before, during, and after treatment is 
administered and will be given sterile water and the same type of food. After viral infection, the 
mice will be monitored daily for morbidity (body weight) and mortality, as well as subjected to a 
blood test every two days. Blood IL-6 levels and blood plasma BK levels will be analyzed and 
recorded for all mice.  
When the mice begin to exhibit an inflammatory response, the drug treatments will begin. 
The first group will be given the IL-6 inhibitor Actemra, which is approved for use against a 
cytokine storm in Covid-19 patients, over a 14-day period. All symptoms will be recorded, as 
well as any changes, in addition to measurements of IL-6 and BK levels. The second group will 
be given icatibant, an FDA-approved BK inhibitor, over a 14-day period, where again all 
symptoms and changes will be recorded, as well as IL-6 and BK levels. These two groups will 
test if one storm is more responsible than the other for the severe Covid-19 responses; if 
treatment with only a BK inhibitor or only an IL-6 inhibitor proves to be effective in mitigating 
the inflammatory response, I can conclude that the corresponding storm is responsible for the 
response. The third group will also test the possibility that both storms are present at the same 
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time. When the third group of mice begin to exhibit an inflammatory response, they will be given 
both Actemra and icatibant over a 14-day period; the BK and IL-6 levels and symptoms will be 
recorded, just as in other groups. The final group is the control, where no treatment will be 
administered except for a mock infection. 
 
C. Potential Outcomes, Caveats, and Alternative Methods 
Cytokine levels have already been observed to be increased in Covid-19 patients. Thus, 
whether IL-6 contributes or does not contribute to the inflammatory response is not necessarily 
the question. However, the cause for the severe inflammatory responses of Covid-19 remain 
unclear. If cytokines are solely responsible for the severe inflammatory response, I would expect 
a decrease in IL-6 levels in the first and third group of mice, in addition to reduction of the 
severity of their symptoms. The same principle applies if a bradykinin storm is solely 
responsible: I will only observe an alleviation in the symptoms of the second and third group of 
animals and a decrease in BK levels. However, because the possibility exists that both could be 
present and potentially acting on one another, I created a third group of mice. If this is the case 
what I expect to observe is little to no change in the symptoms of the mice in groups one and two 
respectively, and an alleviation of symptoms in the third group.  
However, I may also observe a mitigation of the inflammatory response with each single 
drug treatment, where a bradykinin storm might lead to a cytokine storm, or vice versa. I will 
address this outcome in Specific Aim 2. 
There are also some potential concerns. The possibility exists that the mice do not 
generate a storm-like response or do not respond well to the drugs. If the response generated by 
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SARS-CoV-2 infection is too strong or does not appear at all, I will decrease or increase the 
concentration of SARS-CoV-2, respectively. According to previous studies, the inflammatory 
response necessary for this study can be produced (29). Thus, if this problem arises, changing the 
viral load should address this issue (29).  If the mice do not respond well to one or both drugs, or 
if the drugs do not do what they are expected to do, I will find a different IL-6 inhibitor or a 
different BK inhibitor. Ideally, I can use a greater number of mice, or a quantity closer to 30-40 
per group. However, the mice are in low supply and, because of the pandemic, are in high 
demand (28, 29). 
 
Specific Aim 2: Does a bradykinin storm lead to a cytokine storm, or the opposite, if both 
systems play a role? 
A. Rationale:  
Understanding how one pathway functions and potentially affects the other is imperative 
in understanding the roles of BK and IL-6 in generating the observed inflammatory response in 
Covid-19 patients. To test this, single mutations and double mutations will be created and the 
resulting phenotypes will be compared post infection.  
 
B. Research Design 
First I will create single mutants using genetic knockouts. These will be a series of 
mutations to create gain-of-function mutations and loss-of-function mutations. To create a BK 
loss of function, I will delete the BK gene using a CRISPR/Cas9 knockout plasmid that targets 
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the BK gene, so that cells can no longer express BK (30, 36).  To generate a BK gain of function, 
I will induce a bradykinin storm, which can occur when ACE2 is depleted in an organism, since 
it leads to increased levels of DABK (10). Thus, I will use ACE2-deficient mice, the same 
variety used in previous studies of the renin-angiotensin system, to induce overexpression of BK 
(31). Both loss-of-function and gain-of-function models will be bred for homozygosity.  
To create an IL-6 loss-of-function mutation, I will use the transgenic mouse IL6-DIO-
KO, which has lost IL-6 expression (33). To induce an IL-6 gain-of-function, I will use a 
transgenic mouse that use the Clara cell 10-kDa promoter to drive overexpression of IL-6 (32). I 
will also create double mutants, combining loss-of-function and gain-of-function mutations in 
BK and IL-6 in these mouse strains.  
I will then infect the mutant mouse strains with SARS-CoV-2 and record symptoms 
daily, using the same procedure as described in the first specific aim.  
 
C. Potential Outcomes, Caveats, and Alternative Methods. 
A major concern rests with the BK loss-of-function mutant or in the double mutants, for 
example, the mutants expressing loss-of-function mutations in both IL-6 and BK. There is a 
possibility that these mice may not be viable or may present a multitude of health issues and 
might not survive SARS-CoV-2 infection long enough for me to observe responses. The same 
could be true for the mutants expressing both gain-of-function mutations. If this were to happen, 
I would have to find a way to create a reduction-of-function mutation, as opposed to a complete 
loss-of-function mutation, such as introducing siRNAs against BK to create a reduction-of-
function mutation without completely deleting the gene (37). 
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Another potential concern is that ACE2-depleted mice might not cause a BK storm. A 
reduction of ACE2 leads to increased DABK, but there is no guarantee that this alone will cause 
a BK storm in transgenic mice. If this were to happen, an alternative approach would be to 
couple this mutation with another mutation that causes overexpression of BK receptors (38, 39). 
If the phenotype of the double mutants matches one of the single mutations, I can 
conclude the epistasis between the pathways. If the phenotype of the double mutants does not 
match any of the single mutants, then the two pathways might work in parallel. While the exact 
mechanism might not be known on how these two pathways act in parallel, my proposed 
experiments will provide insight on the interaction between the two pathways. 
 
CONCLUSION 
As of July 2021, almost 200 million people have contracted Covid-19 and over 4 million have 
died (40). While the fatality rate has certainly decreased over time, the effects of the pandemic 
changed daily life drastically for many (41). The long-term effects of the disease remain largely 
unknown because of its recent occurrence, and it becomes increasingly imperative that the 
mechanisms of human immunity are understood to prevent the deaths of millions. This was not 
the first pandemic that we have encountered and will certainly not be the last. Understanding the 
body’s adaptive and innate immune responses will allow us to create treatments for future 
epidemics and pandemics. This may also allow us to predict the way future strains might affect 
our bodies before they bloom into devastating pandemics. A further understanding of how 
bradykinins and cytokines function together to create the inflammatory responses observed as a 
result of SARS-CoV-2 infection and other diseases is also absolutely critical in developing 
effective treatments for these diseases. Knowing how both pathways potentially interact with one 
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another would allow us to prevent prolonged tissue damage in the instance of a bradykinin or a 
cytokine storm. Besides Covid-19, my study should also yield insight into the study of other 
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